Is fibromyalgia a central nervous system disorder?

What was previously believed about fibromyalgia?

For decades, fibromyalgia was often dismissed as a psychosomatic or 'all in your head' condition, or misdiagnosed as a purely peripheral problem like muscle or joint disease. This was partly because standard lab tests and imaging often came back normal, leaving doctors without objective evidence [5]. The lack of a clear biological marker led to stigma and delayed diagnosis for many patients.

The older view also focused on tender points and muscle pain, treating fibromyalgia as a rheumatologic condition similar to arthritis. However, recent research has overturned this, revealing that the core problem lies in how the central nervous system processes pain signals, not in the muscles or joints themselves [5].

What does the new evidence show about the CNS role?

The current understanding is that fibromyalgia is a central nervous system disorder characterized by 'central sensitization' — a state where the brain and spinal cord amplify pain signals. This is supported by multiple lines of evidence. For instance, brain imaging studies have found that fibromyalgia patients have reduced cortical thickness in key brain regions involved in pain processing, such as the frontal, temporal, and parietal cortex, compared to healthy controls [6]. These structural changes are a direct sign of CNS involvement.

Further evidence comes from studies showing that fibromyalgia involves neuroinflammation and mitochondrial dysfunction in the CNS. One study in rats found that the condition triggered inflammation and oxidative stress in the spinal cord and prefrontal cortex — key pain-processing areas — and that a treatment targeting these pathways reduced pain behaviors [4]. This suggests that the CNS is not just passively involved but is actively driving the pathology.

Genetic studies also point to the CNS. A 2014 genome-wide analysis found that genetic variations linked to fibromyalgia were in genes related to brain development and function, such as MYT1L and NRXN3, which are involved in neuronal connectivity [7]. This reinforces the idea that fibromyalgia has a neurobiological basis rooted in the CNS.

How does this change treatment approaches?

Recognizing fibromyalgia as a CNS disorder has shifted treatment away from just painkillers and toward therapies that modulate brain function. For example, repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that stimulates specific brain regions, has shown promise. In a randomized controlled trial, fibromyalgia patients who received rTMS over the left prefrontal cortex experienced a greater reduction in depression and disease impact, and a significant increase in vitality, compared to a sham group [1]. This directly targets the CNS rather than peripheral symptoms.

Another CNS-focused approach is electroacupuncture, which was shown in a mouse model to reduce chronic pain by lowering levels of a pain-related protein (TRPV1) in multiple brain regions, including the thalamus and prefrontal cortex [2]. This suggests that treatments that modulate CNS pain pathways can be effective.

However, the CNS focus also explains why many patients are prescribed multiple central nervous system-active medications (like antidepressants, anticonvulsants, and sleep aids). A 2022 study of over 30,000 veterans with fibromyalgia found that 16.2% were on three or more such medications simultaneously, highlighting the complexity of managing CNS symptoms [3]. This underscores the need for careful, coordinated treatment plans.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2014 to 2026, 4 from 2024 or later, 5 in Q1 journals, collectively cited 130 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 52 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions